Review of the Paediatric Pleuropulmonary Blastoma French Series
NCT ID: NCT03044834
Last Updated: 2020-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
41 participants
OBSERVATIONAL
2017-01-09
2018-07-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Three histologies are described: type 1 purely cystic, type 2 combined and type 3 solid. Median age at diagnostic is 12 months, 35 months and 41 months respectively. Evolution is possible from type 1 to type 2 or 3 in 10% of the cases.
Since 2009, DICER 1 mutations research is proposed systematically to all families.
PPB symptoms are usually non-specific. Diagnostic is evoked when imaging work up shows bubbles or solid lesions, and confirmed by pathological analysis. However the diagnosis can be difficult because of the proximity with congenital cystic adenomatoid malformation.
The French society of paediatric oncology recommends surgery at first instance. PPB type 1 remains a problem because some are still misdiagnosed as CCAM, a benign lesion. Chemotherapy depends on the PPB type and the quality of the resection. There is a real interest to analyse the French series.
The prognosis of type 2 and 3 is low with a 5 years survival rate of 45-60%, whereas type 1 survival rate is 91%. The French experience reports a 100% survival rate in type 1 and 48% in type 2 and 3. Other prognostic factors are initial size of the tumour, extra pulmonary invasion and quality of surgery.
Early local relapses are possible and late ones concern more often type 2 and 3 with more cerebral metastasis.
In 2009, the french cases were collected, but no update has been performed since. The aim of this retrospective review of the cases since 2000, is to audit the care of PPB patients in France and update the French rare tumour database.
Evoking PPB diagnosis is difficult when imaging shows a neonatal cystic lesion. There are no radiologic criteria in the literature that differentiate congenital pulmonary cystic lesion and PPB type 1. Radiological presentation is however overlapping. Another aim of this study will be to look for a predictive sign of type 1 PPB.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Infantile Hemangioma With Minimal or Arrested Growth : Epidemiology, Clinical Characteristics and Evolution
NCT05080868
Impact of Tumour 1q Gain in French Pediatric and Young Adult Patients With Renal Tumours
NCT04005820
Ultrasound Diagnosis of Cleft Lip and Palate
NCT03582111
Therapeutic Recommendations for Nephroblastoma
NCT04423484
Stone Disease of the Urinary Tract in Children
NCT06032364
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pleuropulmonary Blastoma
* Patients born between 01/01/2000 and 01/01/2016 ;
* Followed up for PPB
* Treated in a French department of paediatric oncology or paediatric surgery
* Study agreement
PPB
Global current care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PPB
Global current care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Followed up for PPB
* Treated in a French department of paediatric oncology or paediatric surgery
* Study agreement
Exclusion Criteria
* Study disagreement
1 Year
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rennes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexis ARNAUD, MD
Role: PRINCIPAL_INVESTIGATOR
Rennes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Angers University Hospital
Angers, , France
Bordeaux University Hospital
Bordeaux, , France
Caen University Hospital
Caen, , France
Grenoble University Hospital
Grenoble, , France
Kremlin-Bicêtre Hospital
Le Kremlin-Bicêtre, , France
Lille University Hospital
Lille, , France
Lyon Universty Hospital
Lyon, , France
Marseille University Hospital
Marseille, , France
Montpellier University Hospital
Montpellier, , France
Nantes University Hospital
Nantes, , France
Nice University Hospital
Nice, , France
Necher Hospital
Paris, , France
Poitiers University Hospital
Poitiers, , France
Curie Institute
Saint-Cloud, , France
Réunion University Hospital
Saint-Paul, , France
Toulouse University Hospital
Toulouse, , France
Tours University Hospital
Tours, , France
Gustave Roussy Institute
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15.18
Identifier Type: OTHER
Identifier Source: secondary_id
15.468
Identifier Type: OTHER
Identifier Source: secondary_id
915465
Identifier Type: OTHER
Identifier Source: secondary_id
35RC15_3009_PPB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.